NBSE logo

NeuBase Therapeutics (NBSE) Selling, General & Administrative Expenses

Annual SG&A

$11.87 M
-$332.50 K-2.72%

30 September 2022

3-Year Change

-2.72%
NBSE annual selling, general & administrative expenses is down -2.72% over the past 3 years

All-time High

$12.20 M
NBSE annual selling, general & administrative expenses is currently -2.72% below its historical high of $12.20 million
Annual Total Expenses$33.32 M
NBSE annual total expenses is $33.32 million
Annual Operating Expenses$33.32 M
NBSE annual total operating expenses is $33.32 million
Annual Net Income-$33.78 M
NBSE annual net profit is -$33.78 million

NBSE Selling, General & Administrative Expenses Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly SG&A

$1.20 M
-$1.20 M-49.95%

30 September 2023

3-Year Change

-64.29%
NBSE quarterly selling, general & administrative expenses is down -64.29% over the past 3 years

All-time High

$6.63 M
NBSE quarterly selling, general & administrative expenses is currently -81.86% below its historical high of $6.63 million
Quarterly Total Expenses$1.59 M
NBSE quarterly total expenses is $1.59 million
Quarterly Operating Expenses$1.59 M
NBSE quarterly total operating expenses is $1.59 million
Quarterly Net Income-$1.82 M
NBSE quarterly net profit is -$1.82 million

NBSE Quarterly SG&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM SG&A

-$449.45 M
-$13.73 M-3.15%

30 September 2023

3-Year Change

-3783.33%
NBSE TTM selling, general & administrative expenses is down -3783.33% over the past 3 years

All-time High

$14.26 M
NBSE TTM selling, general & administrative expenses is currently -3252.54% below its historical high of $14.26 million
Annual Total Expenses$33.32 M
NBSE annual total expenses is $33.32 million
Annual Operating Expenses$33.32 M
NBSE annual total operating expenses is $33.32 million
TTM Net Income-$13.73 M
NBSE TTM net profit is -$13.73 million

NBSE TTM SG&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NBSE Selling, General & Administrative Expenses Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year---
3 y3 years-2.7%-64.3%-3783.3%
5 y5 years+30.5%-81.9%-5041.4%

NBSE Selling, General & Administrative Expenses High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years
5 y5 years
alltimeall time-2.7%-81.9%-3252.5%

NeuBase Therapeutics Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sept 2023
-
$1.20 M(-50.0%)
$9.12 M(-10.2%)
June 2023
-
$2.40 M(-17.6%)
$10.15 M(-10.6%)
Mar 2023
-
$2.92 M(+12.4%)
$11.35 M(-1.5%)
Dec 2022
-
$2.60 M(+16.1%)
$11.53 M(-2.9%)
Sept 2022
$11.87 M(-2.7%)
$2.24 M(-37.9%)
$11.87 M(-8.7%)
June 2022
-
$3.60 M(+16.5%)
$13.00 M(+1.0%)
Mar 2022
-
$3.09 M(+5.4%)
$12.87 M(+3.0%)
Dec 2021
-
$2.94 M(-12.9%)
$12.50 M(+2.4%)
Sept 2021
$12.20 M(+20.5%)
$3.37 M(-2.9%)
$12.20 M(+7.7%)
June 2021
-
$3.47 M(+27.5%)
$11.33 M(+11.2%)
Mar 2021
-
$2.72 M(+3.0%)
$10.19 M(-0.2%)
Dec 2020
-
$2.64 M(+5.7%)
$10.21 M(+0.9%)
Sept 2020
$10.12 M(+11.3%)
$2.50 M(+7.2%)
$10.12 M(-29.0%)
June 2020
-
$2.33 M(-14.9%)
$14.26 M(+11.3%)
Mar 2020
-
$2.74 M(+7.2%)
$12.81 M(+16.8%)
Dec 2019
-
$2.55 M(-61.5%)
$10.97 M(+20.6%)
Sept 2019
$9.10 M(+150.3%)
$6.63 M(+646.4%)
$9.10 M(+187.6%)
June 2019
-
$888.50 K(-0.7%)
$3.16 M(+1.7%)
Mar 2019
-
$894.40 K(+31.3%)
$3.11 M(+10.8%)
Dec 2018
-
$681.00 K(-2.5%)
$2.81 M(-22.8%)
Sept 2018
$3.63 M(-31.1%)
$698.60 K(-16.3%)
$3.63 M(-0.7%)
June 2018
-
$834.70 K(+41.2%)
$3.66 M(-13.5%)
Mar 2018
-
$591.20 K(-60.8%)
$4.23 M(-16.1%)
Dec 2017
-
$1.51 M(+108.7%)
$5.04 M(-4.5%)
Sept 2017
$5.28 M(-31.1%)
$723.60 K(-48.5%)
$5.28 M(-17.0%)
June 2017
-
$1.40 M(+0.0%)
$6.36 M(-3.9%)
Mar 2017
-
$1.40 M(-19.6%)
$6.62 M(-19.1%)
Dec 2016
-
$1.75 M(-3.4%)
$8.18 M(+6.9%)
Sept 2016
$7.66 M(+2.0%)
$1.81 M(+8.5%)
$7.66 M(+0.1%)
June 2016
-
$1.66 M(-43.9%)
$7.65 M(+1.5%)
Mar 2016
-
$2.97 M(+143.5%)
$7.54 M(-4.7%)
Dec 2015
-
$1.22 M(-32.4%)
$7.91 M(+5.4%)
Sept 2015
$7.51 M(+75.2%)
$1.80 M(+15.9%)
$7.51 M(+3.7%)
June 2015
-
$1.55 M(-53.4%)
$7.24 M(+11.9%)
Mar 2015
-
$3.33 M(+310.5%)
$6.47 M(+44.7%)
Dec 2014
-
$812.50 K(-47.0%)
$4.47 M(+3.3%)
Sept 2014
$4.29 M
$1.53 M(+95.1%)
$4.33 M(+36.1%)
June 2014
-
$785.90 K(-41.3%)
$3.18 M(-4.0%)
Mar 2014
-
$1.34 M(+100.0%)
$3.31 M(+50.0%)
DateAnnualQuarterlyTTM
Dec 2013
-
$669.10 K(+73.3%)
$2.21 M(+24.4%)
Sept 2013
$1.78 M(+6.9%)
$386.00 K(-58.0%)
$1.78 M(-13.4%)
June 2013
-
$919.30 K(+292.2%)
$2.05 M(+45.1%)
Mar 2013
-
$234.40 K(-0.8%)
$1.41 M(-18.5%)
Dec 2012
-
$236.20 K(-64.3%)
$1.74 M(+4.5%)
Sept 2012
$1.66 M(+130.2%)
$661.70 K(+134.9%)
$1.66 M(+28.7%)
June 2012
-
$281.70 K(-49.4%)
$1.29 M(+8.5%)
Mar 2012
-
$556.30 K(+245.5%)
$1.19 M(+51.6%)
Dec 2011
-
$161.00 K(-44.8%)
$784.70 K(+3.9%)
Sept 2011
$721.40 K(+1.2%)
$291.70 K(+61.5%)
$755.50 K(+34.1%)
June 2011
-
$180.60 K(+19.3%)
$563.30 K(-22.1%)
Mar 2011
-
$151.40 K(+14.9%)
$722.80 K(+4.4%)
Dec 2010
-
$131.80 K(+32.5%)
$692.20 K(-2.9%)
Sept 2010
$713.00 K(-21.5%)
$99.50 K(-70.7%)
$713.10 K(-10.6%)
June 2010
-
$340.10 K(+181.5%)
$797.80 K(+18.3%)
Mar 2010
-
$120.80 K(-20.9%)
$674.30 K(-32.2%)
Dec 2009
-
$152.70 K(-17.1%)
$993.90 K(+9.5%)
Sept 2009
$908.40 K(+36.3%)
$184.20 K(-15.0%)
$907.60 K(-12.4%)
June 2009
-
$216.60 K(-50.8%)
$1.04 M(+24.3%)
Mar 2009
-
$440.40 K(+563.3%)
$833.40 K(+70.4%)
Dec 2008
-
$66.40 K(-78.8%)
$489.00 K(-26.5%)
Sept 2008
$666.60 K(>+9900.0%)
$312.60 K(+2132.9%)
$665.60 K(+88.6%)
June 2008
-
$14.00 K(-85.4%)
$353.00 K(+4.1%)
Mar 2008
-
$96.00 K(-60.5%)
$339.00 K(-69.5%)
Dec 2007
-
$243.00 K(>+9900.0%)
$1.11 M(+23.8%)
Sept 2007
$0.00(-100.0%)
$0.00(0.0%)
$896.90 K(-1.0%)
June 2007
-
$0.00(-100.0%)
$906.00 K(0.0%)
Mar 2007
-
$867.00 K(+2799.7%)
$906.00 K(+134.2%)
Dec 2006
$85.00 K(-94.2%)
$29.90 K(+228.6%)
$386.80 K(-78.2%)
Sept 2006
-
$9100.00(-97.4%)
$1.78 M(-31.8%)
Mar 2006
-
$347.80 K(-75.5%)
$2.61 M(-0.0%)
Dec 2005
$1.46 M(+10.9%)
$1.42 M(+272.2%)
$2.61 M(+67.8%)
Sept 2005
-
$381.30 K(-16.5%)
$1.55 M(+4.3%)
June 2005
-
$456.90 K(+30.9%)
$1.49 M(+10.7%)
Mar 2005
-
$349.10 K(-4.7%)
$1.35 M(+2.2%)
Dec 2004
$1.32 M(+17.4%)
$366.20 K(+15.3%)
$1.32 M(+38.5%)
Sept 2004
-
$317.70 K(+1.4%)
$951.40 K(+50.1%)
June 2004
-
$313.20 K(-2.3%)
$633.70 K(+97.7%)
Mar 2004
-
$320.50 K
$320.50 K
Dec 2003
$1.12 M
-
-

FAQ

  • What is NeuBase Therapeutics annual selling, general & administrative expenses?
  • What is the all time high annual SG&A for NeuBase Therapeutics?
  • What is NeuBase Therapeutics quarterly selling, general & administrative expenses?
  • What is the all time high quarterly SG&A for NeuBase Therapeutics?
  • What is NeuBase Therapeutics TTM selling, general & administrative expenses?
  • What is the all time high TTM SG&A for NeuBase Therapeutics?

What is NeuBase Therapeutics annual selling, general & administrative expenses?

The current annual SG&A of NBSE is $11.87 M

What is the all time high annual SG&A for NeuBase Therapeutics?

NeuBase Therapeutics all-time high annual selling, general & administrative expenses is $12.20 M

What is NeuBase Therapeutics quarterly selling, general & administrative expenses?

The current quarterly SG&A of NBSE is $1.20 M

What is the all time high quarterly SG&A for NeuBase Therapeutics?

NeuBase Therapeutics all-time high quarterly selling, general & administrative expenses is $6.63 M

What is NeuBase Therapeutics TTM selling, general & administrative expenses?

The current TTM SG&A of NBSE is -$449.45 M

What is the all time high TTM SG&A for NeuBase Therapeutics?

NeuBase Therapeutics all-time high TTM selling, general & administrative expenses is $14.26 M